Sanofi is to acquire UK biotech Kymab in a deal worth up to $1.45 billion as the big French pharma seeks to add to its pipeline of drugs that treat inflammatory diseases and cancer. Cambridge-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback